Custom Pharma Services
Harry Whittington ACMA, CGMA is a seasoned finance professional with extensive experience in various leadership roles across multiple industries. As the Director and Owner of Optimal Finance Solutions, Harry focuses on enhancing SMEs' profitability and cash flow while building resilient financial structures. In the role of Fractional CFO at Custom Pharma Services, Harry leads the Finance and IT functions, contributing to business strategy alongside the Senior Leadership Team. Previous positions include Finance Director and Head of Finance & IT, where achievements included leading the successful implementation of ERP systems, negotiating significant asset financing agreements, and improving cash flow management. With a Bachelor's degree in Economics, Finance, and Banking from the University of Portsmouth, Harry combines hands-on expertise with strategic financial insights to drive sustainable growth.
This person is not in any teams
Custom Pharma Services
1 followers
Custom Pharma Services is located in Brighton, UK since 1979 and is a full-service contract development and manufacturing organisation (CDMO) providing services tailored to your needs, no matter how niche or complex. Custom covers the full spectrum of activities from development through commercial manufacturing for both clinical and commercial use. Specialising in Oral Solid Dosage forms with the ability to handle highly potent drugs and poorly bioavailable compounds Custom really is your one stop resource. With direct access to highly skilled experts offering a partnership approach Custom Pharma Services truly has a molecule first mentality, managing all projects with the end in mind. Custom Can! • Custom Pharma is a CDMO offering clinical and commercial manufacturing of tablets, capsules, powders (oral-solid-dose) for human use. • Services comprise pre-formulation and formulation development, analytical development, stability testing, clinical trial material manufacturing • Commercial Production • Pre-clinical formulation development and solubilisation • Material characterisation • Drug in capsule approach to accelerate early clinical studies • Specialists in low dosage (sub-mg) formulations • Contained manufacturing for highly potent APIs • Orphan drug development • Formulation development of poorly soluble drugs, including spray drying capabilities